Sanofi India Limited has received an order vacating a tax demand of Rs 72,71,510 for Assessment Year 2019-20, following a favourable decision by the Commissioner of Income Tax Appeal (CIT(A)). The Assistant Commissioner of Income Tax, TDS OSD TDS Circle 2(2), Mumbai, passed the order on August 11, 2026, giving effect to the appellate order dated July 2, 2026. This resolution concludes proceedings initiated under Section 201 of the Income-tax Act, 1961, regarding non-deduction of Tax Deducted at Source (TDS) on year-end provisions.

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Sanofi India Limited had previously intimated the stock exchanges on July 3, 2026, regarding the receipt of the favourable Appellate Order. The final order formally deletes the demand, providing closure to the specific tax dispute for the relevant assessment year.

Order Details

Financial Impact

The company stated that there is no material impact on the financial, operational, or other activities of Sanofi India Limited. The vacated demand relates to a past assessment year and does not affect current period profitability or cash flows. The resolution removes a contingent liability associated with the earlier tax proceedings.

Regulatory Compliance

Haresh Vala, Company Secretary and Compliance Officer at Sanofi India Limited, submitted the disclosure to the Bombay Stock Exchange and the National Stock Exchange of India Limited. The filing confirms compliance with SEBI LODR Regulations, ensuring transparency for investors regarding significant regulatory developments affecting the company's tax position.

Sanofi India Limited reported a 19% year-on-year increase in profit before tax (PBT) to ₹112 crore for the quarter ended June 30, 2026, driven by strong performance in its diabetes franchise and disciplined cost management. The company’s domestic sales grew by 8%, offsetting a 2% decline in exports, resulting in a 7% overall top-line growth. This financial outcome underscores the effectiveness of Sanofi’s strategic pivot toward high-growth therapeutic areas and operational efficiency following last year’s organizational transformation.

The results were disclosed during an investor call held on August 5, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript was filed with the BSE and NSE on August 10, 2026. Management highlighted that the PBT margin expanded from 24% to 27% of net sales on a quarterly basis, reflecting improved profitability despite headwinds in the partnership segment.

Financial Performance Highlights

The company’s total income rose by 7%, primarily driven by a 6% growth in combined domestic and export sales. Other operating income contributed significantly, largely stemming from services provided to group entities, including private companies and consumer health divisions. Other income included interest on deposits and foreign exchange gains.

For the first half of FY27 (H1), profit before tax declined by 4% year-on-year, impacted by one-off transition costs in the partnership segment during Q1. However, excluding these transitional items, management noted that the underlying top-line would have been positive, and the bottom-line would have shown high-digit growth.

Business Segment Analysis

The diabetes business unit emerged as the primary growth engine, delivering 14% double-digit growth in Q2. This performance was powered by the innovative portfolio of Toujeo and Soliqua. Deepak Arora, Managing Director, attributed 70% of this growth to disciplined execution and expansion in the public sector, including new state accounts and care segments. The company maintains a 47% market share by value in the diabetes sector, with a 58% value share in the basal analog market.

Soliqua continued to grow by 16% quarter-on-quarter, despite erosions in the broader GLP-1 market. Arora emphasized that real-world evidence studies and digital outreach in tier-two and tier-three markets strengthened product positioning. Conversely, the partnership business, managed with Emcure and Cipla, grew by only 2%. Rachid Ayari, CFO, explained that this muted growth resulted from safety stock build-ups in Q1 2025 and aggressive competition in the cardiovascular and CNS segments. He projected that partnership growth may align with industry rates by 2027 as partners reorganize their teams.

Export sales faced challenges, particularly in the Australian market due to heavy competition for mature products. To mitigate these losses, Sanofi is leveraging its Goa manufacturing site for specialized products and targeting tenders in South Africa, France, Italy, Turkey, and Russia. Ayari noted that the company is bringing back previously outsourced CMO volumes to the Goa site to boost capacity utilization.

What the Numbers Show

A critical observation from the Q2 results is the divergence between top-line stability and bottom-line expansion. While overall sales growth remained modest at 7%, the 19% surge in PBT indicates significant operating leverage. The 5% quarter-on-quarter reduction in operating expenses, focused on personnel costs without impacting key projects, directly contributed to the margin expansion from 24% to 27%. This suggests that the strategic transformation completed last year is yielding immediate financial benefits through cost discipline, even as the partnership segment undergoes a transitional phase. The robust 34% year-on-year growth in cash reserves further validates the company’s financial health, providing flexibility for future investments or shareholder returns.

Corporate Social Responsibility and Outlook

Sanofi India also updated investors on its CSR initiatives, stating it is ahead of schedule for 2026 commitments. The company aims to reach over 600,000 direct beneficiaries through programs like KiDS & Diabetes in Schools and Mobile Medical Units. A recent MoU with the National Health Mission in Madhya Pradesh expands early screening and treatment access for non-communicable diseases.

Looking ahead, management expressed optimism about sustaining diabetes growth, citing a large pool of underdiagnosed patients in India. Arora confirmed that while once-weekly insulins like Novo Nordisk’s Awiqli present new options, the core patient base for once-daily basal analogs remains stable. The company plans to continue leveraging AI platforms and innovative devices to streamline patient journeys from screening to treatment.